Compounds which have activity at M1 receptor and their uses in medicine

US8288412B2 · kind B2 · utility

Assignee

• Glaxo Group Limited · GB

Inventors

• Brian W. Budzik · Perkiomenville, US
• David G. Cooper · Riva, US
• Ian Thomson Forbes · Harlow, GB
• Vincenzo Garzya · Harlow, GB
• Jian Jin · Suzhou, CN
• Dongchuan Shi · Collegeville, US
• Paul William Smith · Harlow, GB
• Graham Walker · Harlow, GB

Key dates

• Filing date: Sep 27, 2006
• Grant date: Oct 16, 2012
• Expiry date: Dec 16, 2029

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of formula (I) and salts are provided:wherein R5 is selected from halogen, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C1-6 alkoxy, C1-6 alkoxy substituted with one or more fluorine atoms, and cyano; R6 is selected from halogen, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C3-6cycloalkyl, C3-6cycloalkyl substituted with one or more fluorine atoms, C1-6 alkoxy, C1-6 alkoxy substituted with one or more fluorine atoms, and cyano; and Q is hydrogen or C1-6alkyl. The compounds are M1 agonists and are useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.